Form 4: X4 Pharmaceuticals COO Receives 650,000 Restricted Stock Units
SEC Form 4 Filing
Mary DiBiase, COO of X4 Pharmaceuticals, was granted 650,000 restricted stock units under the company's equity incentive plan.
Summary
- Mary DiBiase, the Chief Operating Officer of X4 Pharmaceuticals, received 650,000 restricted stock units on February 12, 2025.
- These units were granted under the company's Amended and Restated 2017 Equity Incentive Plan.
- Each restricted stock unit represents the right to receive one share of common stock upon vesting.
- No payment was made upon the grant of these units.
- The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027, and February 12, 2028, contingent upon continued employment with X4 Pharmaceuticals.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock units is a standard practice and indicates confidence in the executive's continued contribution to the company. However, it doesn't provide any groundbreaking news or financial insights.
Positives
- The grant of restricted stock units aligns the COO's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
Risks
- The value of the restricted stock units is dependent on the future performance of X4 Pharmaceuticals' stock.
Future Outlook
The vesting of the restricted stock units is contingent upon the COO's continued employment with X4 Pharmaceuticals, suggesting an expectation of her continued service.
Industry Context
Grants of restricted stock units are a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock grants are a typical component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation to align executive interests with shareholder value.
Stakeholder Impact
- Shareholders may view the grant positively as it aligns management's interests with the company's long-term performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of the transaction: Grant of 650,000 restricted stock units. |
| 02/12/2026 | First vesting date for the restricted stock units (one-third). |
| 02/12/2027 | Second vesting date for the restricted stock units (one-third). |
| 02/12/2028 | Final vesting date for the restricted stock units (one-third). |
| 02/14/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.